PDF(Pubmed)
Abstract：
UNASSIGNED: To retrospectively study the effects of budesonide inhalation combined with conventional symptomatic treatment on serum inflammatory factor expression levels and pulmonary function in patients with cough variant asthma (CVA) and to evaluate treatment efficacy.
UNASSIGNED: This retrospective cohort study included 200 patients diagnosed with CVA at the Second Hospital of Jiaxing between January 2022 and June 2023 and given conventional symptomatic treatment plus budesonide inhalation were included in this study. Patients were divided into a no remission group, a partial remission group and a complete remission group based on treatment effect. The expression levels of serum inflammatory factors, cough symptom scores, and small airway function indicators in the three groups of patients at different time points were compared.
UNASSIGNED: In the three groups of CVA patients, after receiving budesonide inhalation combined with conventional symptomatic treatment, the expression levels of serum IL-5, IL-6, IL-8, TNF-α, TGF-β1, and IgE and number of eosinophils significantly decreased (P <0.05). There were statistically significant differences in the IL-6 and TGF-β1 levels among the three groups of CVA patients at T1, T2 and T3. There were statistically significant differences in IgE levels, number of eosinophils, cough symptom scores, and small airway function indicators between T2 and T3 (P<0.05). The receiver operating characteristic (ROC) curve prediction analysis revealed significant differences in the expression of IL-6 and TGF-β1 at T1, T2, and T3.
UNASSIGNED: Budesonide inhalation combined with conventional symptomatic treatment can significantly reduce the levels of serum inflammatory factors in patients with CVA to reduce inflammation and the allergic response, thereby reducing the cough symptom score, improving pulmonary function, and improving therapeutic efficacy. In addition, IL-6 and TGF-β1 can be used as early predictors of budesonide inhalation efficacy.
UNASSIGNED: This retrospective cohort study included 200 patients diagnosed with CVA at the Second Hospital of Jiaxing between January 2022 and June 2023 and given conventional symptomatic treatment plus budesonide inhalation were included in this study. Patients were divided into a no remission group, a partial remission group and a complete remission group based on treatment effect. The expression levels of serum inflammatory factors, cough symptom scores, and small airway function indicators in the three groups of patients at different time points were compared.
UNASSIGNED: In the three groups of CVA patients, after receiving budesonide inhalation combined with conventional symptomatic treatment, the expression levels of serum IL-5, IL-6, IL-8, TNF-α, TGF-β1, and IgE and number of eosinophils significantly decreased (P <0.05). There were statistically significant differences in the IL-6 and TGF-β1 levels among the three groups of CVA patients at T1, T2 and T3. There were statistically significant differences in IgE levels, number of eosinophils, cough symptom scores, and small airway function indicators between T2 and T3 (P<0.05). The receiver operating characteristic (ROC) curve prediction analysis revealed significant differences in the expression of IL-6 and TGF-β1 at T1, T2, and T3.
UNASSIGNED: Budesonide inhalation combined with conventional symptomatic treatment can significantly reduce the levels of serum inflammatory factors in patients with CVA to reduce inflammation and the allergic response, thereby reducing the cough symptom score, improving pulmonary function, and improving therapeutic efficacy. In addition, IL-6 and TGF-β1 can be used as early predictors of budesonide inhalation efficacy.
摘要：
■回顾性研究布地奈德雾化吸入联合常规对症治疗对咳嗽变异性哮喘(CVA)患者血清炎性因子表达水平及肺功能的影响，并评价治疗效果。
■这项回顾性队列研究纳入了2022年1月至2023年6月在嘉兴市第二医院诊断为CVA并给予常规对症治疗加布地奈德雾化吸入的200例患者。将患者分为未缓解组，根据治疗效果设置部分缓解组和完全缓解组。血清炎症因子的表达水平,咳嗽症状评分,比较三组患者不同时间点的小气道功能指标。
■在三组CVA患者中，布地奈德雾化吸入联合常规对症治疗后,血清IL-5、IL-6、IL-8、TNF-α、TGF-β1、IgE和嗜酸性粒细胞数量明显下降(P<0.05)。3组CVA患者在T1、T2、T3时IL-6和TGF-β1水平差异均有统计学意义。IgE水平差异有统计学意义,嗜酸性粒细胞的数量，咳嗽症状评分,小气道功能指标在T2和T3之间(P<0.05)。受试者工作特征（ROC）曲线预测分析显示，在T1，T2和T3时，IL-6和TGF-β1的表达存在显着差异。
■布地奈德雾化吸入联合常规对症治疗可显著降低CVA患者血清炎症因子水平，减轻炎症反应，减轻过敏反应，从而降低咳嗽症状评分，改善肺功能，提高治疗效果。此外,IL-6和TGF-β1可作为布地奈德吸入疗效的早期预测因子。
■这项回顾性队列研究纳入了2022年1月至2023年6月在嘉兴市第二医院诊断为CVA并给予常规对症治疗加布地奈德雾化吸入的200例患者。将患者分为未缓解组，根据治疗效果设置部分缓解组和完全缓解组。血清炎症因子的表达水平,咳嗽症状评分,比较三组患者不同时间点的小气道功能指标。
■在三组CVA患者中，布地奈德雾化吸入联合常规对症治疗后,血清IL-5、IL-6、IL-8、TNF-α、TGF-β1、IgE和嗜酸性粒细胞数量明显下降(P<0.05)。3组CVA患者在T1、T2、T3时IL-6和TGF-β1水平差异均有统计学意义。IgE水平差异有统计学意义,嗜酸性粒细胞的数量，咳嗽症状评分,小气道功能指标在T2和T3之间(P<0.05)。受试者工作特征（ROC）曲线预测分析显示，在T1，T2和T3时，IL-6和TGF-β1的表达存在显着差异。
■布地奈德雾化吸入联合常规对症治疗可显著降低CVA患者血清炎症因子水平，减轻炎症反应，减轻过敏反应，从而降低咳嗽症状评分，改善肺功能，提高治疗效果。此外,IL-6和TGF-β1可作为布地奈德吸入疗效的早期预测因子。
